CUV: 10th year of profit, strong cash, Nasdaq move, and major R&D catalysts in vitiligo and peptides
CUV: 10th year of profit, strong cash, Nasdaq move, and major R&D catalysts in vitiligo and peptides
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.